Furthermore, we observed a poor response and decreased OS of the lung cancer patients with the variants rs3764821 (ALDH3B1) and rs3748523 (RAD52) for both first- and second-line chemotherapy. This evidence concerns the gene RAD52 and lung carcinoma.